US orders Vaxart to stop COVID-19 trial amid mRNA wind down
Vaxart halts COVID trial enrollment due to government funding cuts. Several biotech firms face similar loss of support for vaccine programs.
View signal analysisCompany intelligence
VXRT
Vaxart, Inc. · NASDAQ · Healthcare
Price$0.57+7.17% · +$0.04
Market cap138.57MEquity value
P / E3.8Trailing ratio
Volume52.47KLatest session
Market data
TradingViewVXRT price chart
Related signals
1 min delayedLatest VXRT price-moving signals
Browse public VXRT signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Oppenheimer initiated coverage on Vaxart, highlighting its oral vaccine potential. The analyst set a $4 price target, indicating significant upside for VXRT. Vaxart leads in developing an oral vaccine for norovirus, addressing unmet needs. BARDA funding supports VXRT's COVID-19 vaccine development and potential market impact. The company's oral vaccine may enhance immunity compared to traditional methods.
View signal analysisResearch